Nájera LA, Zatarain OAS, López MJA

Language: Spanish
References: 21
Page: 31-35
PDF size: 226.37 Kb.

ABSTRACT

Background: HIV/AIDS-associated lymphomas are neoplasms that develop from T and B lymphocytes. People with HIV have a 20 times higher risk of developing non- Hodgkin lymphoma than the general population.
Clinical case: A 52-year-old male patient, with HIV under control with antiretroviral therapy, last viral load undetectable, attended due to growth of a 12 x 14 cm mass in the right side of the neck, fever, dysphagia and dysphonia. Histopathological study reported a proliferative diffuse undifferentiated lesion corresponding to non-Hodgkin lymphoma. The immunohistochemical study documented a high-grade B-cell lymphoma derived from the germinal center, Burkitt type associated with Epstein-Barr virus (CD20+, BCL6+, CD10+, C-MYC+, EBER+, proliferation index 100%, double hit). Treatment with DA-EPOCH-R was started, achieving a reduction in the size of the mass to 6 x 6 cm after the second cycle. The patient is currently in good clinical condition, in the fourth cycle of DA-EPOCH-R, with no masses or palpable lymph nodes.
Conclusions: Double-hit non-Hodgkin lymphoma, Burkitt type associated with Epstein-Barr virus in patients with HIV is rarely reported in the literature; however, its early diagnosis is essential to the correct staging of the disease and start treatment in a timely manner, given the high rate of proliferation and the high rates of treatment failure, relapse or death.

REFERENCES

1. Berhan A, Bayleyegn B, Getaneh Z. HIV/AIDS associatedlymphoma: review. Blood Lymphat Cancer 2022; 12: 31-45.doi: 10.2147/BLCTT.S361320

2. Tazi I, Lahlimi FZ. Virus de l’immunodéficience humaineet lymphome [Human immunodeficiency virus and lymphoma].Bull Cancer 2021; 108 (10): 953-62. https://doi.org/10.1016/j.bulcan.2021.03.014

3. Giordano D, Castellucci A, Merli F, Garlassi E, Pernice C. HIVrelatednon-Hodgkin lymphoma: case report and reviewof the literature. Acta Biomed 2019; 89 (4): 576-80. doi:10.23750/abm.v89i4.6627

4. Alli N, Meer S. Head and neck lymphomas: a 20-yearreview in an oral pathology unit, Johannesburg, SouthAfrica, a country with the highest global incidence of HIV/AIDS. Oral Oncol 2017; 67: 17-23. doi: 10.1016/j.oraloncology.2017.01.011

5. Saleh K, Michot JM, Camara-Clayette V, Vassetsky Y, RibragV. Burkitt and Burkitt-like lymphomas: a systematicreview. Curr Oncol Rep 2020; 22 (4): 33. doi: 10.1007/s11912-020-0898-8

6. Casulo C, Friedberg JW. Burkitt lymphoma - a rare but challenginglymphoma. Best Pract Res Clin Haematol 2018; 31(3): 279-84. doi: 10.1016/j.beha.2018.07.013

7. Atallah-Yunes SA, Murphy DJ, Noy A. HIV-associated Burkittlymphoma. Lancet Haematol 2020; 7 (8): 594-600. DOI:10.1016/S2352-3026(20)30126-5

8. Crombie J, LaCasce A. The treatment of Burkitt lymphomain adults. Blood 2021; 137 (6): 743-50. doi: 10.1182/blood.2019004099

9. Merron B, Davies A. Double hit lymphoma: how do we defineit and how do we treat it? Best Pract Res Clin Haematol2018; 31 (3): 233-40. doi: 10.1016/j.beha.2018.07.012

10. Johnson PC, Abramson JS. Current treatment of Burkittlymphoma and high-grade B-cell lymphomas.Oncology (Williston Park) 2022; 36 (8): 499-505. doi:10.46883/2022.25920970

11. Thandra KC, Barsouk A, Saginala K, Padala SA, et al. Epidemiologyof non-Hodgkin’s lymphoma. Med Sci (Basel)2021; 9 (1): 5. doi: 10.3390/medsci9010005

12. Laude MC, Lebras L, Sesques P, Ghesquieres H, et al. Firstlinetreatment of double-hit and triple-hit lymphomas:survival and tolerance data from a retrospective multicenterFrench study. Am J Hematol 2021; 96 (3): 302-11.doi: 10.1002/ajh.26068

13. Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 updateon diagnosis, risk stratification, and treatment. AmJ Hematol 2019; 94 (5): 604-16. doi: 10.1002/ajh.25460

14. Novo M, Castellino A, Nicolosi M, Santambrogio E, etal. High-grade B-cell lymphoma: how to diagnose andtreat. Expert Rev Hematol 2019; 12 (7): 497-506. doi:10.1080/17474086.2019.1624157

15. Mehta A, Verma A, Gupta G, Tripathi R, Sharma A. Doublehit and double expresser diffuse large B cell lymphomasubtypes: discrete subtypes and major predictors of overallsurvival. Indian J Hematol Blood Transfus 2020; 36 (4):627-34. doi: 10.1007/s12288-019-01248-w

16. Phuoc V, Sandoval-Sus J, Chavez JC. Drug therapy fordouble-hit lymphoma. Drugs Context. 2019; 8: 2019-8-1.doi: 10.7573/dic.2019-8-1

17. Chapman JR, Bouska AC, Zhang W, Alderuccio JP, et al. EBVpositiveHIV-associated diffuse large B cell lymphomas arecharacterized by JAK/STAT (STAT3) pathway mutations andunique clinicopathologic features. Br J Haematol 2021; 194(5): 870-8. doi: 10.1111/bjh.17708

18. Dunleavy K. Double-hit lymphoma: optimizing therapy.Hematology Am Soc Hematol Educ Program 2021;2021 (1): 157-63. https://doi.org/10.1182/hematology.2021000247

19. Ting CY, Chang KM, Kuan JW, Sathar J, et al. Clinical significanceof BCL2, C-MYC, and BCL6 genetic abnormalities,Epstein-Barr virus infection, CD5 protein expression, germinalcenter B cell/non-germinal center B-cell subtypes,co-expression of MYC/BCL2 proteins and co-expressionof MYC/BCL2/BCL6 proteins in diffuse large B-cell lymphoma:a clinical and pathological correlation study of120 patients. Int J Med Sci 2019; 16 (4): 556-66. doi:10.7150/ijms.27610

20. Dodero A, Guidetti A, Marino F, Tucci A, et al. DoseadjustedEPOCH and rituximab for the treatment ofdouble expressor and double-hit diffuse large B-celllymphoma: impact of TP53 mutations on clinical outcome.Haematologica 2022; 107 (5): 1153-62. doi: 10.3324/haematol.2021.278638

21. Dunleavy K, Fanale MA, Abramson JS, Noy A, et al. DoseadjustedEPOCH-R (etoposide, prednisone, vincristine,cyclophosphamide, doxorubicin, and rituximab) in untreatedaggressive diffuse large B-cell lymphoma with MYCrearrangement: a prospective, multicentre, single-armphase 2 study. Lancet Haematol 2018; 5 (12): 609-17. doi:10.1016/S2352-3026(18)30177-7